Thind Komal, Padrnos Leslie J, Ramanathan Ramesh K, Borad Mitesh J
Department of Internal Medicine, Cleveland Clinic Akron General, Akron, OH, USA.
Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Therap Adv Gastroenterol. 2017 Jan;10(1):168-194. doi: 10.1177/1756283X16667909. Epub 2016 Oct 17.
Pancreatic cancer is a highly aggressive and lethal cancer characterized by high invasiveness, local and extensive dissemination at time of diagnosis and resistance to treatment. Few therapies have shown efficacy in the past and even standard of care therapies yield only modest improvements in the mortality of patients with advanced or metastatic disease. Efforts have been undertaken to study the pancreatic tumor microenvironment and have established its complex and immunosuppressive nature which could explain the high resistance to chemotherapy. Novel therapies targeting the tumor microenvironment with an aim to decrease this resistance, improve immune tolerance and increase the efficacy of the current treatment have shown some promising preliminary results in preclinical and clinical trials. We review the current advances in the field of immunotherapy and their effectiveness as a potential treatment strategy in the pancreatic cancer.
胰腺癌是一种极具侵袭性和致命性的癌症,其特点是侵袭性强、在诊断时局部和广泛扩散以及对治疗耐药。过去很少有疗法显示出疗效,即使是标准的护理疗法也只能使晚期或转移性疾病患者的死亡率略有改善。人们已努力研究胰腺肿瘤微环境,并确定了其复杂的免疫抑制性质,这可以解释对化疗的高耐药性。旨在通过靶向肿瘤微环境来降低这种耐药性、改善免疫耐受性并提高当前治疗效果的新型疗法,在临床前和临床试验中已显示出一些有前景的初步结果。我们综述了免疫治疗领域的当前进展及其作为胰腺癌潜在治疗策略的有效性。